Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (NYSE: AZN) reported positive high-level results from the global Phase III CLARITY-Gastric01 trial, in which sonesitatug vedotin (Sone‑Ve), an anti‑CLDN18.2 antibody-drug conjugate, showed a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus investigator’s choice of therapy in 3rd and later-line CLDN18.2‑positive advanced gastric, gastroesophageal junction (GEJ) cancer and esophageal adenocarcinoma.
The trial enrolled patients whose tumors expressed CLDN18.2 in ≥25% of cells and met its dual primary endpoint of OS in 3rd and later-line treatment, as well as a key secondary endpoint of OS in the overall 2nd and later-line population. Progression‑free survival, the other dual primary endpoint, showed a trend toward improvement in the 2nd and later-line setting but did not reach statistical significance. Sone‑Ve was well tolerated with no new safety signals and is being positioned for a broad CLDN18.2‑positive population, estimated at about 60% of gastric/GEJ cancers, representing roughly 183,500 2nd and later-line patients annually across the US, EU, China and Japan.
AstraZeneca (NASDAQ:AZN) reported H1 2026 Total Revenue of $30.7bn, up 9% reported and 6% at CER, with Product Revenue of $30.6bn. H1 Reported EPS was $3.60 (up 4% reported, 3% CER) and Core EPS was $5.21 (up 12% reported, 11% CER).
Q2 2026 Total Revenue was $15.4bn, up 6% reported and 5% CER, with Gross Margin at 84% and Core Operating Margin at 34%. The interim dividend increased by 3 cents to $1.06 per share. Guidance for 2026 at CER is reconfirmed: Total Revenue to grow mid-to-high single digits and Core EPS by a low double-digit percentage.
The company highlighted 30 major approvals since Q4 2025, mixed Phase III readouts, and two sizeable licensing deals: a global licence for lung cancer drug Zegfrovy ($600m upfront, up to $900m milestones) and a respiratory PDE3/4 inhibitor TQC3721 ($200m upfront, up to $1.9bn milestones).
AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) plus pertuzumab has received a positive CHMP opinion in the EU as first-line treatment for adults with unresectable or metastatic HER2 positive breast cancer. The recommendation, based on the phase 3 DESTINY-Breast09 trial, will now be reviewed by the European Commission.
According to the companies, the combination reduced the risk of disease progression or death by 44% versus taxane + trastuzumab + pertuzumab (THP), with median progression-free survival of 40.7 months versus 26.9 months. Confirmed objective response rate was 85.1% with Enhertu plus pertuzumab versus 78.6% with THP, and median duration of response reached 39.2 months versus 26.4 months. The safety profile was described as consistent with known profiles of each drug; treatment-related grade ≥3 neutropenia occurred in 23.9% of patients and adjudicated interstitial lung disease or pneumonitis in 12.1%, including 0.5% grade 5 events.
Abbisko Therapeutics and AstraZeneca (NYSE:AZN) entered a strategic collaboration to develop an IO-TKI combination for EGFR-mutated, PD-L1 positive NSCLC. A multicenter, open-label Phase I/II trial will test Abbisko’s oral PD-L1 inhibitor lumipodlin (ABSK043) with AstraZeneca’s TAGRISSO (osimertinib). The investigational new drug application for this combination was cleared by China’s NMPA on May 20, 2026, and Abbisko will lead the Phase II study, with both companies sharing trial responsibilities.
AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo received European Commission approval for Enhertu as the first tumor-agnostic HER2-directed antibody drug conjugate. The monotherapy is indicated for adults with unresectable or metastatic HER2 positive (IHC 3+) solid tumors after prior treatment and without satisfactory options.
Approval is based on three phase 2 trials (DESTINY-PanTumor02, -Lung01, -CRC02), showing confirmed ORRs of 52.3%, 52.9% and 46.9% and median DORs up to 21.1 months. A $25 million milestone payment is due from AstraZeneca to Daiichi Sankyo.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) received a positive CHMP opinion in the EU as first-line monotherapy for unresectable or metastatic triple negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.
TROPION-Breast02 showed 5.0-month median overall survival gain (23.7 vs 18.7 months; HR=0.79) and longer progression-free survival (10.8 vs 5.6 months; HR=0.57) versus chemotherapy, plus higher objective response rate (62.5% vs 29.3%). Datroway is already approved in the US and under review in several other regions.
AstraZeneca (NYSE:AZN) and YMCA of the USA announced a five-year, multimillion-dollar partnership to strengthen community-based cancer education and survivorship support across the US.
The initiative aims to reach 175,000 people in 75 communities in its first two years, focusing on screening, early detection, and evidence-based programs for cancer survivors.
AstraZeneca (NASDAQ:AZN) announced US FDA approval of TRUQAP (capivasertib) plus abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, detected by an FDA‑authorized test.
In Phase III CAPItello‑281, the combination reduced risk of radiographic progression or death by 19% (HR 0.81; 95% CI 0.66–0.98; p=0.034) and improved median rPFS to 33.2 vs 25.7 months. Overall survival data are immature but numerically favor the TRUQAP regimen. A companion PTEN diagnostic was approved alongside the indication.
Common Grade ≥3 adverse events with the prostate regimen included rash (12.3%) and hyperglycemia (10.3%), and 20% of patients discontinued TRUQAP due to adverse reactions.
AstraZeneca (AZN) reported updated Phase III SERENA-6 results in HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation. Switching to camizestrant + CDK4/6 inhibitor reduced first progression or death by 55% (PFS 16.8 vs 9.2 months) and second progression or death by 37% (PFS2 25.7 vs 19.1 months) versus aromatase inhibitor combinations.
Median total ctDNA changed −99% with camizestrant versus +64% with standard care; 51% achieved ctDNA clearance vs 1.9%. Chemotherapy/ADC-free survival was 22.6 vs 18.7 months. Safety was consistent with known profiles. Camizestrant is approved in UAE and Saudi Arabia, with EU, US, Japan and other reviews ongoing.
AstraZeneca (AZN)/b) reported EMERALD-3 Phase III data in embolization-eligible unresectable hepatocellular carcinoma. IMFINZI (durvalumab) plus IMJUDO (tremelimumab-actl), lenvatinib and TACE cut the risk of progression or death by versus TACE alone (PFS HR 0.70; median PFS 13.0 vs 9.8 months).
The STRIDE plus TACE arm also showed clinically meaningful PFS and OS improvements versus TACE, with median PFS 12.9 vs 8.1 months. Grade ≥3 adverse events occurred in 71.4% and 64% of patients in the investigational arms, compared with 28.6% for TACE alone.